Structure-Activity Relationship of Aza-Steroids as PI-PLC Inhibitors

Bioorg. Med. Chem. 9 (2001) 1073

Wenge Xie, a Hairuo Peng, Deog-Il Kim, Mark Kunkel, Garth Powish and Leon H. Zalkowa

^aSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332, USA ^bArizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, Tucson, AZ 85724-5024, USA

The 20α epimer (8a2) of 22,25-diazacholesterol, the most potent of a number of azasteroids tested (IC $_{50}$ of 0.64 μ M), was 50 times more potent than the epimeric 20 β isomer (8a1) as a PIPLC inhibitor. The epimeric mixture (8a) of compounds 8a1 and 8a2 (1:1) exhibited selective growth inhibition effects in the NCI in vitro tumor cell screen with a GI $_{50}$ MG-MID values of 5.75 μ M for 54 human tumors.

8a1 (20 β , IC₅₀ = 32.2 μ M) **8a2** (20 α , IC₅₀ = 0.64 μ M)

Mechanism of Biochemical Action of Substituted Benzopyran-2-ones.

Bioorg. Med. Chem. 9 (2001) 1085

Part 8: Acetoxycoumarin: Protein Transacetylase Specificity for Aromatic Nuclear Acetoxy Groups in Proximity to the Oxygen Heteroatom

Hanumantharao G. Raj,^a Ekta Kohli,^a Rajeev Goswami,^b Sanjay Goel,^a Ramesh C. Rastogi,^b Subhash C. Jain,^b Jesper Wengel,^c Carl E. Olsen^d and Virinder S. Parmar^b

^aDepartment of Biochemistry, V. P. Chest Institute, University of Delhi, Delhi 110 007, India

^bDepartment of Chemistry, University of Delhi, Delhi 110 007, India

^cDepartment of Chemistry, University of Southern Denmark, DK-5230 Odense M, Denmark

^dChemistry Department, Royal Veterinary and Agricultural University, DK-1871 Frederiksberg C, Copenhagen, Denmark AcO

The specificity for transacetylase action on various acetoxycoumarins demonstrates that the acetoxycoumarin having the acetoxy substituent nearest to the pyrone ring oxygen of the coumarin moiety is the best substrate for the transacetylase.

C-3,C-4, C-5, C-6, C-7 monoacetoxy or C-7, C-8 diacetoxycoumarin

Glycosidase Inhibitors of *gem*-Diamine 1-*N*-iminosugars: Structures in Media of Enzyme Assays

Bioorg. Med. Chem. 9 (2001) 1091

Ken-ichiro Kondo, Hayamitsu Adachi, Eiki Shitara, Fukiko Kojima and Yoshio Nishimura *Institute of Microbial Chemistry*, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan

gem-Diamine 1-N-iminosugars (1 and 2) change the structures to 4 and 6 via 3 and 5, respectively in media, and the products (3–6) as well as the parent compounds (1, 2) potently inhibit glycosidases.

Inhibition of the HIV-1 Rev-RRE Complex Formation by Unfused Aromatic Cations

Bioorg. Med. Chem. 9 (2001) 1097

Ge Xiao, Arvind Kumar, Ke Li, C. Ted Rigl, Miroslav Bajic, Tina M. Davis, David W. Boykin* and W. David Wilson*

Department of Chemistry, Georgia State University, Atlanta, GA 30303, USA

A diphenylfuran lead compound was systematically varied and the ability of the new compounds to inhibit the formation of Rev–RRE and Tat–TAR complexes was assayed by gel-mobility shift experiments. In this series, DB340 was found to be the most active compound and also the most specific compound for inhibition of Rev–RRE complex formation.

Construction of Peptide Conjugates with Peptide Nucleic Acids Containing an Anthracene Probe and Their Interactions with DNA

Bioorg. Med. Chem. 9 (2001) 1115


Ganesan Balasundaram, a Tsuyoshi Takahashi, a Akihiko Ueno a and Hisakazu Mihara hisakazu Mihara a,b

^aDepartment of Bioengineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Nagatsuta, Yokohama 226-8501, Japan

^bForm and Function, PRESTO, Japan Science and Technology Corporation, Tokyo Institute of Technology, Nagatsuta, Yokohama 226-8501, Japan

α-Helix peptides containing thymine PNA oligomers at the C-terminus were designed and synthesized. Two anthracene chromophores were used as probes and functional groups. Incorporation of thymine PNA oligomer into the designed peptide influenced the DNA binding property, especially with

[d(AT)₁₀dA₆]₂ without changing the conformations of anthracene side chain and the peptide.



Synthesis and Antiviral/Antitumor Evaluation of 2-Amino- and 2-Carboxamido-3-arylsulfonylthiophenes and Related Compounds as a New Class of Diarylsulfones

Chad E. Stephens, a Takita M. Feldera, J. Walter Sowell, Sr., Graciela Andrei, b Jan Balzarini,^b Robert Snoeck^b and Erik De Clercq^b

^aDivision of Medicinal Chemistry, College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA

^bRega Institute of Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

Certain title compounds have exhibited activity against HIV-1, CMV, VZV, and/or various human tumor cell lines. Compounds 8d and 13d, for example, inhibit CMV at concentrations < 1 μg/mL.

Bioorg. Med. Chem. 9 (2001) 1123

Substrate Specificity of *N*-Acetylglucosaminyl(diphosphodolichol) N-Acetylglucosaminyl Transferase, a Key Enzyme in the Dolichol Pathway

Bioorg. Med. Chem. 9 (2001) 1133

Vincent W.-F. Tai, Mary K. O'Reilly and Barbara Imperiali

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA


Unnatural dolichol diphosphate monosaccharides (X = F, OEt, NHCOCF₃, NH₂) were synthesized to probe the substrate specificity of N-acetylglucosaminyl(diphosphodolichol) N-acetylglucosaminyl transferase, also known as Enzyme II, from pig liver.

An *Octakis*-Intercalating Molecule

Bioorg. Med. Chem. 9 (2001) 1141

Meredith M. Murr, Matthew T. Harting, Vladimir Guelev, Jinsong Ren, Jonathan B. Chaires and Brent L. Iversona,*

^aDepartment of Chemistry and Biochemistry, The University of Texas at Austin, Austin, TX 78712, USA ^bDepartment of Biochemistry, University of Mississippi Medical School, MS, USA



Synthesis and Cytotoxicity Evaluation of Novel Indolylpyrimidines and Indolylpyrazines as Potential Antitumor Agents

Biao Jiang, Cai-Guang Yang, Wen-Nan Xiong and Jun Wang

Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, P. R. China

The synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents is reported.

Coupling between Substrate Binding and Allosteric Regulation in Ribozyme Catalysis

Michihiro Araki, Mie Hashima, Yasushi Okuno and Yukio Sugiura Institute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan

The contribution of substrate binding to allosteric regulation in the rate process of ribozyme catalysis has been investigated.

Bioorg. Med. Chem. 9 (2001) 1155

Structure–Activity Relationships in 2,2-Diphenyl-2-ethylthioacetic Acid Esters: Unexpected Agonistic Activity in a Series of Muscarinic Antagonists

Bioorg. Med. Chem. 9 (2001) 1165

S. Scapecchi,^a G. Marucci,^b R. Matucci,^c P. Angeli,^b C. Bellucci,^a M. Buccioni,^b S. Dei,^a F. Gualtieri,^a D. Manetti,^a M. N. Romanelli^a and E. Teodori^a

^aDipartimento di Scienze Farmaceutiche, Universita' di Firenze, Via Gino Capponi 9, 50121 Firenze, Italy

^bDipartimento di Scienze Chimiche, Universita' di Camerino, Via S. Agostino 1, 62032 Camerino, Italy

^cDipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, viale Pieraccini 6, 50139 Firenze, Italy

A series of derivatives of 2,2-diphenyl-2-ethylthioacetic acid were synthetised and their antimuscarinic activity of $M_{1\!-\!4}$ receptor subtype was evaluated by functional tests and binding experiments. One of the compounds obtained showed unexpected agonistic activity in functional experiments on M_2 receptors. Other compounds carrying a phenylpiperazine moiety (12–17) were prepared and found to be endowed with similar behaviour.

The Synthesis and Evaluation of Benzofuranones as β -Lactamase Substrates

Bioorg. Med. Chem. 9 (2001) 1175

S.A. Adediran, a D. Cabaret, B. Drouillat, R.F. Pratta and M. Wakselman^b

^aDepartment of Chemistry, Wesleyan University, Middletown, CT 06459, USA

^bSIRCOB, ESA CNRS 8086, Université de Versailles, Bât. Lavoisier, 45, avenue des Etats Unis F-78075, Versailles, France

Structure-Activity Studies of FIV and HIV Protease Inhibitors Containing Allophenylnorstatine

Van-Duc Le,^a Chi Ching Mak,^a Ying-Chuan Lin,^b John H. Elder^b and Chi-Huey Wong^a

^aDepartment of Chemistry and the Skaggs Institute for Chemical Biology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

^bDepartment of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA OPh H OPh OH S OME

VLE776 HIV PR (IC₅₀) = 8 nM FIV PR (IC₅₀) = 48 nM

Structure–Activity Studies Leading to (–)1-(Benzofuran-2-yl)-2-propylaminopentane, ((–)BPAP), a Highly Potent, Selective Enhancer of the Impulse Propagation Mediated Release of Catecholamines and Serotonin in the Brain

Fumio Yoneda,^a Toshiaki Moto,^a Masatoshi Sakae,^a Hironori Ohde,^a Berta Knoll,^b Ildikó Miklya^b and Joseph Knoll^b

^aResearch Institute, Fujimoto Pharmaceutical Corporation, Matsubara, Osaka 580-8503, Japan

^bDepartment of Pharmacology, Semmelweis University of Medicine, POB 370, Budapest H-1445, Hungary

Bioorg. Med. Chem. 9 (2001) 1197

Enantioselective Synthesis and Absolute Configuration of (-)-1-(Benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a Highly Potent and Selective Catecholaminergic Activity Enhancer

Takahiro Oka, a Takuya Yasusa, a Takashi Ando, a Mayumi Watanabe, a Fumio Yoneda, a Toshimasa Ishida and Joseph Knollc

^aResearch Institute, Fujimoto Pharmaceutical Corporation, 1-3-40, Nishiotsuka, Matsubara, Osaka 580-8503, Japan

^bOsaka Universzity of Pharmaceutical Science, 4-20-1, Nasahara, Takatsuki, Osaka 569-1094, Japan

^cDepartment of Pharmacology, Semmelweis University of Medicine, P.O.B. 370, Budapest H-1445, Hungary

Bioorg. Med. Chem. 9 (2001) 1213

Pleuromutilins. Part 1: The Identification of Novel Mutilin 14-Carbamates

Bioorg. Med. Chem. 9 (2001) 1221

Gerald Brooks, ^a Wendy Burgess, ^c David Colthurst, ^c Jeremy D. Hinks, ^c Eric Hunt, ^a Michael J. Pearson, ^c Burdena Shea, ^c Andrew K. Takle, ^a Jennifer M. Wilson ^c and Gary Woodnutt ^b

^aSmithKline Beecham Pharmaceuticals Research and Development, Discovery Chemistry Europe, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK

^bSmithKline Beecham Pharmaceuticals Research and Development, Microbiology Research, 1250 South Collegville Road, Collegville, PA 19426, USA ^cSmithKline Beecham Pharmaceuticals Research and Development, Brockham Park, Betchworth, Surrey RH3 7AJ, UK

A novel series of mutilin 14-carbamates have been identified, for example SB-222734 (150), which have potent antibacterial activity against a number of clinically relevant bacterial pathogens.

Synthesis of N-substituted N-nitrosohydroxylamines as Inhibitors of Mushroom Tyrosinase

Mitsuhiro Shiino, a Yumi Watanabea and Kazuo Umezawab

^aLaboratory of Chemistry, School of Medicine, Keio University, 4-1-1 Hiyoshi, Kohoku-ku, Yokohama 223-0061, Japan ^bDepartment of Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-0061, Japan

A series of N-substituted N-nitrosohydroxylamines were synthesized and their inhibitory effects on mushroom tyrosinase were examined. Among them, N-cyclopentyl-N-nitrosohydroxylamine (9) was found to be the most potent inhibitor($IC_{50} = 0.6 \,\mu\text{M}$).

9

Synthesis and Application of a Novel, Crystalline Phosphoramidite Monomer with Thiol Terminus, Suitable for the Synthesis of DNA Conjugates

Zoltán Kupihár, a Zoltán Schmél, b Zoltán Kele, a Botond Penkea and Lajos Kovácsa

^aDepartment of Medicinal Chemistry, Dóm tér 8, University of Szeged, H-6720 Szeged, Hungary

^bDepartment of Pharmaceutical Analysis, Somogyi B. u. 4, University of Szeged, H-6720 Szeged, Hungary

A new crystalline 5'-thiol modifier phosphoramidite monomer (n=2), suitable for DNA synthesis, has been prepared. This monomer has been built into an oligonucleotide using the standard protocol. After cleavage, purification and removal of the trityl group with Ag^+ , a free 5'-thiol terminal oligonucleotide has been obtained which was subsequently coupled to a cysteine derivative via a disulfide bridge to afford a conjugate.

Bioorg. Med. Chem. 9 (2001) 1241

A Possible Prebiotic Synthesis of Purine, Adenine, Cytosine, and 4(3H)-Pyrimidinone from Formamide: Implications for the Origin of Life

Bioorg. Med. Chem. 9 (2001) 1249

Raffaele Saladino, a Claudia Crestini, b Giovanna Costanzo, c Rodolfo Negrid and Ernesto Di Mauroc, d

^aDipartimento A.B.A.C., Università della Tuscia, 01100 Viterbo, Italy

^bDipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata, 00133 Rome, Italy

°Fondazione Istituto Pasteur, Fondazione Cenci Bolognetti c/o Dipartimento di Genetica e Biologia Molecolare, Università di Roma La Sapienza, 00185 Rome, Italy

dCentro di Studio per gli Acidi Nucleici, CNR, 00185 Rome, Italy

Human DNA Topoisomerase I Inhibitory Activities of Synthetic Polyamines: Relation to DNA Aggregation

Bioorg. Med. Chem. 9 (2001) 1255

Alyona Sukhanova, a Jerome Dêvy, a Michel Pluot, a Jean-Claude Bradley, b Jean-Pierre Vigneron, c Jean-Claude Jardillier, a Jean-Marie Lehn and Igor Nabieva

^aEA2063, Université de Reims Champagne-Ardenne, 51100 Reims, France

^bDepartment of Chemistry, Drexel University, Philadelphia, PA 19107, USA

°UPR 285, Collège de France, 75005 Paris, France

Structure-function correlation of seven synthetic tetramines and hexamines in terms of their DNA aggregation abilities and human DNA topoisomerase I inhibition activities.

α - and β -Homogalactonojirimycins (α - and β -Homogalactostatins): Synthesis and Further Biological Evaluation

Olivier R. Martin, a.* Oscar M. Saavedra, a Fang Xie, Li Liu, Sylviane Picasso, Pierre Vogel, Haruhisa Kizuc and Naoki Asanoc

^aDepartment of Chemistry, State University of New York, Binghamton, NY 13902-6016, USA

^bInstitut de Chimie Organique, Université de Lausanne, BCH, 1015 Lausanne, Switzerland

^cFaculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa 920-11, Japan

The synthesis of α - and β -homogalactonojirimycins 3 and 4 and their activities as inhibitors of glycosidases are reported. Compound 3 is a good inhibitor of human lysosomal α-galactosidase A.

 $3 R_1 = H, R_2 = CH_2OH$ 4 $R_1 = CH_2OH, R_2 = H$

Synthesis and Immunological Activity of Water-Soluble Thalidomide **Prodrugs**


Sonja Hess,^a Michaela A. Akermann,^a Stephan Wnendt,^b Kai Zwingenberger^c and Kurt Egera

^aUniversity of Leipzig, Institute of Pharmacy, Pharmaceutical Chemistry, Brüderstrasse 34, D-04103 Leipzig, Germany

^bMolecular Pharmacology Department, Grünenthal, Zieglerstrasse 8, D-52068 Aachen, Germany

^cMedical Scientific Division, Grünenthal, Zieglerstrasse 8,

D-52068 Aachen, Germany



Bioorg. Med. Chem. 9 (2001) 1293

Bioorg. Med. Chem. 9 (2001) 1279

Theoretical Investigation of (-)1-(Benzofuran-2-yl)-2propylaminopentane [(-)-BPAP] as a Hydroxyl Radical Scavenger

Sachiko Nakai and Fumio Yoneda

Fujimoto Pharmaceutical Corporation, 1-3-40 Nishi-Otsuka, Matsubara-shi, Osaka 580-8503, Japan

The chemical reactions between (-)-BPAP and •OH were studied using molecular orbital theory, with several simplified models.

Design and Synthesis of New Orally Active Inhibitors of Human **Neutrophil Elastase**

Bioorg. Med. Chem. 9 (2001) 1307

Kazuyuki Ohmoto, Motohiro Okuma, Tetsuya Yamamoto, Hideomi Kijima, Tomohiko Sekioka, Kanji Kitagawa, Shigeki Yamamoto, Kenji Tanaka, Kazuhito Kawabata, Atsushi Sakata, Haruo Imawaka, Hisao Nakai and Masaaki Toda

Minase Research Institute, Ono Pharmaceutical Co., Ltd., Shimamoto, Mishima, Osaka 618-8585, Japan

A Multireceptorial Binding Reinvestigation on an Extended Class of σ Ligands: N-[ω -(Indan-1-yl and Tetralin-1-yl)alkyl] Derivatives of 3,3-Dimethylpiperidine Reveal High Affinities Towards σ_1 and EBP Sites

Francesco Berardi, Savina Ferorelli, Nicola Antonio Colabufo, Marcello Leopoldo, Roberto Perrone and Vincenzo Tortorella

Dipartimento Farmaco-Chimico, Università di Bari, via Orabona 4, I-70126 Bari, Italy

New and known N-[ω (indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine were tested at σ_1 and σ_2 receptor, L-type Ca⁺⁺ channel and EBP (Δ_8 - Δ_7 sterol isomerase) site, showing high σ_1 affinity and moderate or low σ_2 affinity. 1-[4-(2,3-Dihydro-1H-inden-1-yl)butyl]-3,3-dimethylpiperidine (**26**) is the best mixed σ_1 and EBP ligand (apparent K_i =1.75 and 1.54 nM, respectively) with a good selectivity versus σ_2 receptor (138- and 157-fold, respectively).

$$R_1$$
 R_2
 R_3

New Synthesis of (\pm) - α -CMBHC and Its Confirmation as a Metabolite of α -Tocopherol (Vitamin E)

Bioorg. Med. Chem. 9 (2001) 1337

Simon A.S. Pope, a Guillaume E. Burtin, Peter T. Clayton, David J. Madgeb and David P.R. Muller

^aBiochemistry, Endocrinology and Metabolism Unit, The Institute of Child Health, University College London, London, WC1N 1EH, UK

^bBiological and Medicinal Chemistry, The Wolfson Institute for Biomedical Research, University College London, London, WC1E 6AU, UK

Lipase Catalysed Synthesis of Optically Enriched α-Haloamides

Bioorg. Med. Chem. 9 (2001) 1345

Bioorg. Med. Chem. 9 (2001) 1349

Abul Azim, a Sunil K. Sharma, a Carl E. Olsen and Virinder S. Parmara

^aDepartment of Chemistry, University of Delhi, Delhi-110 007, India

^bChemistry Department, Royal Veterinary and Agricultural University, DK-1871 Frederiksberg C, Copenhagen, Denmark

Lipase catalysed synthesis of optically enriched α -haloamides with concomitant optical enrichment of the starting α -haloesters is described. *Candida antarctica* lipase (CAL) was found to be a better catalyst over porcine pancreatic lipase (PPL) and *Candida cylindraceae* lipase (CCL). The effect of different organic solvents was also studied.

$$\begin{array}{c}
R \downarrow 0 \\
\downarrow 0 \\
X \\
(+)
\end{array}$$

$$\begin{array}{c}
CAL \\
40^{\circ}C, DIPE
\end{array}$$

$$\begin{array}{c}
R \downarrow 0 \\
X \\
H
\end{array}$$

$$\begin{array}{c}
R^{1} + R \downarrow 0 \\
X \\
(-)
\end{array}$$

$$\begin{array}{c}
CC_{2}H_{5}
\end{array}$$

 $X = Br,CI; R = CH_3,CH_3(CH_2)_4; R^1 = C_7H_7,C_6H_{11}$

Synthesis and Structure–Affinity Relationships of 4-(5-Aryl-1,2,3,6-tetrahydropyridino)pyrimidine Derivatives as Corticotropin-Releasing Factor₁ Receptor Antagonists

Toshihito Kumagai, Taketoshi Okubo, Hiromi Kataoka-Okubo, Shigeyuki Chaki, Shigeru Okuyama and Atsuro Nakazato

1st Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Ohmiya, Saitama 330-8530, Japan

This paper describes the synthesis and structure–affinity relationships of 4-(5-aryl-1,2,3,6-tetrahydropyridino)pyrimidine derivatives as corticotropin-releasing factor₁ receptor antagonists.

Chemical Modification of Aryl-1,2,3,6-tetrahydropyridinopyrimidine Derivative to Discover Corticotropin-Releasing Factor₁ Receptor Antagonists: Aryl-1,2,3,6-tetrahydropyridino-purine, -3H-1,2,3-triazolo[4,5-d]pyrimidine, -purin-8-one,

and -7H-pyrrolo[2,3-d]pyrimidine Derivatives

Toshihito Kumagai, Taketoshi Okubo, Hiromi Kataoka-Okubo, Shigeyuki Chaki, Shigeru Okuyama and Atsuro Nakazato

1st Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Ohmiya, Saitama 330-8530, Japan

This paper describes the synthesis and structure-affinity relationships of aryl-1,2,3,6-tetrahydropyridino-purine, -3*H*-1,2,3-triazolo[4,5-*d*]pyridine, -purin-8-one, and -7*H*-pyrrolo[2,3-*d*]pyrimidine derivatives (Y¹-Y²: N=C(H), N=N, N(Me)-C(O) and C(Me)=C(H or Me), respectively) as corticotropin-releasing factor₁ receptor antagonists.